Drug efflux by breast cancer resistance protein is a mechanism of resistance to the benzimidazole insulin-like growth factor receptor/insulin receptor inhibitor, BMS-536924
about
PI3K-AKT-mTOR-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasmsIn silico prediction of inhibition of promiscuous breast cancer resistance protein (BCRP/ABCG2)3-bromopyruvate enhanced daunorubicin-induced cytotoxicity involved in monocarboxylate transporter 1 in breast cancer cellsMammary tumors that become independent of the type I insulin-like growth factor receptor express elevated levels of platelet-derived growth factor receptors.IGFBP ratio confers resistance to IGF targeting and correlates with increased invasion and poor outcome in breast tumors.Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: effect of the dual-receptor inhibitor BMS-536924 in vitro.Type I insulin-like growth factor receptor signaling in hematological malignancies.MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2).Shikonin enhances Adriamycin antitumor effects by inhibiting efflux pumps in A549 cells.Dynamic transitions in RNA polymerase II density profiles during transcription termination.Broad blocking of MDR efflux pumps by acetylshikonin and acetoxyisovalerylshikonin to generate hypersensitive phenotype of malignant carcinoma cells.Synthesis, Characterization, and Crystal Structures of Bis-Imidazolium Salts and Respective Dinuclear Ag(I)N-Heterocyclic Carbene Complexes:In VitroAnticancer Studies against “Human Colon Cancer” and “Breast Cancer”
P2860
Q26862544-4DB0AAE7-8342-4A04-8954-56373BD968E2Q28540667-CCF92CD2-8DE0-4048-B0DE-334B41555A05Q34503166-8A34C683-4CC1-4009-AC2E-DC69956BD08FQ35661710-80307CC9-7618-4DC1-A01C-EFE1E8B4F59FQ35836632-9C2EBD5F-A681-42D9-A102-E05A6E51C40BQ37389178-563F2326-407C-42E2-9A20-3427C03F38CCQ37702186-A35B2B49-49CD-44AB-8010-3851327734CEQ39137771-0E95413B-63EB-4F08-A51C-8EC2BBF937B3Q41701853-D3A8298E-0F5E-4254-9A8F-4C578CF657F9Q42256986-E86E1961-CE16-4D72-9EDE-EB8F8545402EQ53449278-770A8924-1819-48EE-BFB3-2FC26FE61E27Q59010418-99ED0637-BDD5-4F75-94FA-741DDEB57372
P2860
Drug efflux by breast cancer resistance protein is a mechanism of resistance to the benzimidazole insulin-like growth factor receptor/insulin receptor inhibitor, BMS-536924
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Drug efflux by breast cancer r ...... receptor inhibitor, BMS-536924
@ast
Drug efflux by breast cancer r ...... receptor inhibitor, BMS-536924
@en
Drug efflux by breast cancer r ...... receptor inhibitor, BMS-536924
@nl
type
label
Drug efflux by breast cancer r ...... receptor inhibitor, BMS-536924
@ast
Drug efflux by breast cancer r ...... receptor inhibitor, BMS-536924
@en
Drug efflux by breast cancer r ...... receptor inhibitor, BMS-536924
@nl
prefLabel
Drug efflux by breast cancer r ...... receptor inhibitor, BMS-536924
@ast
Drug efflux by breast cancer r ...... receptor inhibitor, BMS-536924
@en
Drug efflux by breast cancer r ...... receptor inhibitor, BMS-536924
@nl
P2093
P2860
P1476
Drug efflux by breast cancer r ...... receptor inhibitor, BMS-536924
@en
P2093
Charles Erlichman
Cynthia Ten Eyck
Douglas D Ross
Jennifer D Tibodeau
Joan M Carboni
Karen Flatten
Marco M Gottardis
Paul Haluska
Xiaonan Hou
P2860
P304
P356
10.1158/1535-7163.MCT-10-0438
P577
2011-01-01T00:00:00Z